158 related articles for article (PubMed ID: 27566090)
1. Remission of Psoriasis in a Patient with Hepatocellular Carcinoma Treated with Sorafenib.
Antoniou EA; Koutsounas I; Damaskos C; Koutsounas S
In Vivo; 2016 09-10; 30(5):677-80. PubMed ID: 27566090
[TBL] [Abstract][Full Text] [Related]
2. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
3. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
4. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
6. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
Ranieri G; Gadaleta-Caldarola G; Goffredo V; Patruno R; Mangia A; Rizzo A; Sciorsci RL; Gadaleta CD
Curr Med Chem; 2012; 19(7):938-44. PubMed ID: 22214462
[TBL] [Abstract][Full Text] [Related]
8. Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.
Moroni M; Zanlorenzi L
Future Oncol; 2013 Aug; 9(8):1231-7. PubMed ID: 23902251
[TBL] [Abstract][Full Text] [Related]
9. Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.
Kwon YC; Bose SK; Steele R; Meyer K; Di Bisceglie AM; Ray RB; Ray R
J Virol; 2015 Nov; 89(22):11549-56. PubMed ID: 26355082
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
Turcios L; Vilchez V; Acosta LF; Poyil P; Butterfield DA; Mitov M; Marti F; Gedaly R
Dig Liver Dis; 2017 Jun; 49(6):697-704. PubMed ID: 28179093
[TBL] [Abstract][Full Text] [Related]
11. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
Maida M; Macaluso FS; Valenza F; Virdone R
J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
[TBL] [Abstract][Full Text] [Related]
12. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
13. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma.
Galmiche A; Chauffert B; Barbare JC
Cancer Lett; 2014 May; 346(2):159-62. PubMed ID: 24380851
[TBL] [Abstract][Full Text] [Related]
14. To treat or not to treat - Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenib.
Waidmann O; Peveling-Oberhag J; Eichler K; Schulze F; Vermehren J
Z Gastroenterol; 2017 Jun; 55(6):564-568. PubMed ID: 27806410
[No Abstract] [Full Text] [Related]
15. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapies for advanced hepatocellular carcinoma.
Sampat KR; O'Neil B
Oncologist; 2013; 18(4):430-8. PubMed ID: 23576483
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.
Yiu ZZ; Ali FR; Griffiths CE
Clin Exp Dermatol; 2016 Jun; 41(4):407-9. PubMed ID: 26667599
[TBL] [Abstract][Full Text] [Related]
19. Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
Elleuch N; Ennaifer R; Romdhane H; Cheikh M; Hefaiedh R; Bougassas W; Ben Nejma H; BelHadj N
Tunis Med; 2015 Jun; 93(6):350-2. PubMed ID: 26644095
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.
Mee CJ; Farquhar MJ; Harris HJ; Hu K; Ramma W; Ahmed A; Maurel P; Bicknell R; Balfe P; McKeating JA
Gastroenterology; 2010 Mar; 138(3):1134-42. PubMed ID: 19944696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
